PepGen Inc.

PepGen Inc.

PEPG·NASDAQ

$1.46

+3.0%
HealthcareBiotechnology

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$101.28M
EPS-2.1200
P/E Ratio-0.69
Earnings Date08/06/2026

pepg

Total Liabilities

Last Annual Value

26.46M

3-Year CAGR

-11%

5-Year CAGR

98%

10-Year CAGR

55%

PepGen Inc.

PepGen Inc. Competitors Analysis of Total Liabilities

PEPG · NASDAQ
CompanyTotal Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
PEPG logo
PepGen Inc.
NASDAQ:PEPG
26.46M
-8.6%20.2%N/A 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
262.59M
-18.6%-12.6%12.8%
NKTX logo
Nkarta, Inc.
NASDAQ:NKTX
91.88M
-4.5%32.0%N/A
29.68M
-25.6%1.6%N/A
6.11M
-60.9%N/AN/A
33.55M
-40.4%-4.1%N/A
102.49M
-7.7%-2.6%N/A
13.30M
23.9%-5.5%N/A
89.66M
-3.5%10.4%N/A
43.95M
45.8%27.8%52.1%
20.69M
-16.2%-11.7%8.7%
PepGen Inc.

PepGen Inc. Fair Value Envelope

PEPG · NASDAQ

Our analysis suggests that PEPG has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.4642, this represents a potential HIDDEN relative to our calculated worth for PepGen Inc..

Intrinsic Value
Current Price: $1.4642